男友太凶猛1v1高h,大地资源在线资源免费观看 ,人妻少妇精品视频二区,极度sm残忍bdsm变态

Global EditionASIA 中文雙語Fran?ais
China
Home / China / Health

Chinese scholars publish biologics guideline in international journal

By Chen Meiling | chinadaily.com.cn | Updated: 2025-05-07 20:26
Share
Share - WeChat

A Chinese guideline on the use of biologic agents in treating chronic rhinosinusitis with nasal polyps was recently published in the 2025 China Issue of Allergy, one of the most prestigious journals in the global fields of allergology and clinical immunology.

It focuses on China-specific clinical data, systematically standardizing key aspects of biologic treatment, such as patient selection, therapeutic protocols and efficacy evaluation, providing authoritative guidance for clinical practice.

"Emerging biologics that selectively target key cytokines present a promising therapeutic alternative for patients suffering from severe, uncontrollable chronic rhinosinusitis with nasal polyps," according to the guideline.

It's the first time that Chinese scholars have published a guideline-type document in a top-tier international journal in this field, offering valuable Chinese experience for global biologic applications, said Zhang Luo, president of Beijing Tongren Hospital and guest editor of the issue, at a news conference in Beijing on Wednesday.

"In the last two decades, the problems of allergic diseases have been increasing dramatically in the world. Now we are facing 2 billion patients with allergic diseases, so this is a serious threat to humankind in the future," he said.

"In the past, we primarily relied on nasal corticosteroid sprays and oral antihistamines, both of which are chemical-based medications. These treatments have been widely used and can effectively control symptoms. However, since they require frequent administration (often daily), patients may find them inconvenient. Now, with these new biologics, just about three injections over an allergy season can effectively manage symptoms. In terms of both efficacy and duration of effect, they represent an improvement over traditional treatments," Zhang said.

He said these medicines are now available in major hospitals, such as in his hospital. However, since biologics are relatively new, their cost remains high — for example, a single injection may cost around 1,000 to 2,000 yuan ($138-276). "But as their use becomes more widespread, prices are expected to gradually decrease, making them more accessible to a larger number of patients," he added.

The 2025 China Issue of Allergy includes 32 articles focusing on the latest research progress of Chinese scholars in areas such as the link between environmental pollution and asthma pathogenesis, gut microbiota dysbiosis and allergies, as well as the mechanisms underlying drug hypersensitivity.

Cezmi Akdis, editor-in-chief of the journal Allergy, the official journal of the European Academy of Allergy and Clinical Immunology, praised China's contribution to the study of allergy, which has "immensely increased" in the last two decades.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
主站蜘蛛池模板: 苗栗县| 罗江县| 湘西| 莱阳市| 云安县| 巫溪县| 汉源县| 东海县| 张家港市| 曲阜市| 鹤山市| 平乐县| 来凤县| 汕头市| 张家港市| 锡林浩特市| 武宣县| 太谷县| 兴国县| 阜阳市| 高邑县| 江达县| 临清市| 衢州市| 娱乐| 广南县| 南丰县| 石楼县| 黄梅县| 尚志市| 景泰县| 应城市| 靖州| 德兴市| 长顺县| 全椒县| 林芝县| 鄂托克前旗| 康定县| 出国| 霍邱县|